Active	Status	Sponsor type	Region	Phase	Filter
17 Active 16 Inactive 33 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
BERGER, Claire
NCT03393975 / 2017-000858-18: A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)	Completed	3	51	Europe, Japan, US	BAX930, rADAMTS13, SHP-655, TAK-755, recombinant ADAMTS13, BAX 930, Standard of care	Baxalta now part of Shire, Takeda Development Center Americas, Inc.	Thrombotic Thrombocytopenic Purpura (TTP)	12/23	05/24
NCT04683003: A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura	Recruiting	3	77	Europe, Japan, US, RoW	TAK-755, rADAMTS13; recombinant ADAMTS13; SHP-655; BAX 930	Takeda, Takeda Development Center Americas, Inc., Shire	Thrombotic Thrombocytopenic Purpura (TTP)	03/27	03/27
BIOMEDE 2, NCT05476939: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0	Recruiting	3	409	Europe	Everolimus, VOTUBIA, AFINITOR, ONC201, Radiotherapy	Gustave Roussy, Cancer Campus, Grand Paris, Chimerix, Innovative Therapies For Children with Cancer Consortium, Ministry of Health, France	Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant	09/28	09/31
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations	Active, not recruiting	2	217	Europe, Japan, US, RoW	tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex	Seagen Inc., Seagen, Inc.	Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms	11/23	05/25
HER2CLIMB-04, NCT04539938: A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer	Active, not recruiting	2	70	US	tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab deruxtecan, T-DXd, Enhertu, DS-8201	Seagen Inc.	HER2 Positive Breast Cancer	07/24	10/25
Protect-NOW, NCT03695978: Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia a Patients	Recruiting	N/A	200	Europe, Canada, US, RoW		Octapharma	Haemophilia a	06/30	06/30
STEPHAN, Jean Louis
No trials found
BARRAL, FABRICE F
No trials found
MASSOUBRE, CATHERINE C
No trials found